Pharma BD Deal Intelligence

Pfizer Inc. / Baxter International Inc. (commercial vaccines portfolio)

2014 · Asset Purchase · $635M · Complete

Announcement Sentiment

Strongly positive

Pfizer agreed to acquire Baxter's commercial vaccines portfolio—NeisVac-C meningococcal vaccine and FSME-IMMUN/TicoVac tick-borne encephalitis vaccine—for $635M cash, complementing its Prevnar franchise. Closed December 1, 2014; aligned with Baxter's preparation to spin off Baxalta.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced Jul 24, 2014
Closed Dec 01, 2014
Deal value $635M
Deal type Asset Purchase
Therapeutic area Meningococcal C and tick-borne encephalitis prophylaxis
Indications Meningococcal C and tick-borne encephalitis prophylaxis
Key assets NeisVac-C and FSME-IMMUN/TicoVac vaccines
Mechanism Conjugate / inactivated viral vaccines

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals